Association of clinical variables with OS
| Variables . | HR . | P value . |
|---|---|---|
| Gender (male vs female) | Inf (0, Inf) | .31 |
| Age, y | — | .41 |
| >70 vs <55 | 2.16 (0.2,23.86) | — |
| 55-70 vs <55 | 0.97 (0.06,15.48) | — |
| Prior lines of therapy, n | — | .28 |
| 3-4 vs >4 | 1.33 (0.15,12.01) | — |
| 1-2 vs >4 | 0 (0, Inf) | — |
| Time from diagnosis to initial vemurafenib therapy, y | — | .18 |
| >15 vs <5 | 1.81 (0.19,17.67) | — |
| 5-15 vs <5 | 0 (0, Inf) | — |
| History of splenectomy | — | .41 |
| Yes vs no | 0 (0, Inf) | — |
| Type of response (best response) | — | .56 |
| CR vs PR | 1.94 (0.2,18.74) | — |
| Cumulative vemurafenib dose (mg) | — | .01 |
| >230 000 vs <150 000 | Inf (0, Inf) | — |
| 150 000-230 000 vs <150 000 | Inf (0, Inf) | — |
| Duration of treatment | — | .09 |
| >90 d vs ≤90 d | Inf (0, Inf) | — |
| Variables . | HR . | P value . |
|---|---|---|
| Gender (male vs female) | Inf (0, Inf) | .31 |
| Age, y | — | .41 |
| >70 vs <55 | 2.16 (0.2,23.86) | — |
| 55-70 vs <55 | 0.97 (0.06,15.48) | — |
| Prior lines of therapy, n | — | .28 |
| 3-4 vs >4 | 1.33 (0.15,12.01) | — |
| 1-2 vs >4 | 0 (0, Inf) | — |
| Time from diagnosis to initial vemurafenib therapy, y | — | .18 |
| >15 vs <5 | 1.81 (0.19,17.67) | — |
| 5-15 vs <5 | 0 (0, Inf) | — |
| History of splenectomy | — | .41 |
| Yes vs no | 0 (0, Inf) | — |
| Type of response (best response) | — | .56 |
| CR vs PR | 1.94 (0.2,18.74) | — |
| Cumulative vemurafenib dose (mg) | — | .01 |
| >230 000 vs <150 000 | Inf (0, Inf) | — |
| 150 000-230 000 vs <150 000 | Inf (0, Inf) | — |
| Duration of treatment | — | .09 |
| >90 d vs ≤90 d | Inf (0, Inf) | — |
Inf, infinity.